Published in Medical Letter on the CDC and FDA, August 8th, 2004
Surfaxin assists with the prevention and treatment of respiratory distress syndrome (RDS) in premature infants. In assessing Surfaxin for orphan drug designation, the COMP concluded that although satisfactory methods of prevention and treatment of RDS have been authorized in Europe, justifications have been provided that Surfaxin may be of significant benefit to those at risk of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA